Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × olaparib × Tumor-Agnostic × Clear all

Phase

Phase 1 13 Phase 2 4 Phase 1/2 2 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 18 Breast 5 Genitourinary 3 Thoracic 2 Gastrointestinal 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1

Conditions

Interventions

Carboplatin 8 Paclitaxel 7 Cisplatin 7 Fluorouracil 6 atezolizumab 5 Trastuzumab 5 Pemetrexed 5 Bevacizumab 5 pembrolizumab 4 Oxaliplatin 4 Leucovorin 4 Gemcitabine 4 Capecitabine 4 Albumin-Bound Paclitaxel 4 Surveys and Questionnaires 3 Observation 3 Leuprolide 3 Irinotecan 3 Glutamine 3 Docetaxel 3 Dexamethasone 3 130-nm albumin-bound paclitaxel 3 regorafenib 2 osimertinib 2 enzalutamide 2 Surgical Procedures, Operative 2 Standard of Care 2 Sorafenib 2 Radiosurgery 2 Radiation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03976362 2026-02-25

KEYLYNK-008

Merck Sharp & Dohme LLC

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡